logo
Plus   Neg
Share
Email

Eli Lilly Announces FDA Approval Of CYRAMZA For New Indication - Quick Facts

Eli Lilly and Company (LLY) announced the FDA has approved CYRAMZA for the treatment of patients with hepatocellular carcinoma who have a high alpha-fetoprotein and have been treated with sorafenib. As a result of the approval of the new indication, FDA has removed the boxed warning from the labeling of CYRAMZA. With the latest approval, the company has now received five FDA approvals for CYRAMZA.

Eli Lilly noted that it has filed applications for marketing authorization in the European Union and Japan for CYRAMZA and regulatory action is expected in mid-2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT